BC Extra | Oct 30, 2014
Top Story

Sanofi ouster opens can of worms

Sanofi (Euronext:SAN; NYSE:SNY) shares touched a 52-week low of $44.50 in New York on Wednesday before its ADSs closed down $2.85 (6%) to $45.22, on the news that Christopher Viehbacher had been removed as CEO,...
BC Extra | Oct 28, 2014
Company News

Sanofi says board not discussing Viehbacher ouster

Sanofi (Euronext:SAN; NYSE:SNY) contradicted press reports that its board of directors planned to discuss ousting CEO Chris Viehbacher at a meeting on Monday. "[T]his ordinary Board meeting is mainly dedicated to the review of the...
BioCentury | Jun 16, 2014
Strategy

Nucleotide arms race

The acquisition of Idenix Pharmaceuticals Inc. will fill a hole in Merck & Co. Inc. 's HCV toolbox and give the pharma a chance to develop an interferon-free regimen that can treat all patients at...
BioCentury | Feb 28, 2000
Finance

The biotech economy

As Old Economy stocks tanked on the Big Board last week, Celera (CRA) demonstrated the new muscle of the biotech space in the New Economy. Stock of the genomics play split 2-1 before the week's...
Items per page:
1 - 4 of 4